Drugs / Netupitant
Netupitant
also known as
NETU · Netupitant component of akynzeo · Netupitant component of akynzeo capsule · RO 67-3189/000 · RO-67-3189
Small molecule targets TACR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Akynzeo | — | 2015-05-27 | europa.eu ↗ |
| Approved | US (FDA) | AKYNZEO | — | 2014-10-10 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07662200 | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04669132 | Dec 2020 → Dec 2021 | chemotherapy-induced toxicity | Instituto Brasileiro de Controle do Cancer | Completed | No outcome recorded |
| Phase 2 | NCT03386617 | Feb 2018 → Dec 2027 expected | breast cancer | Chinese University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03204279 | Aug 2017 → Sep 2019 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT03097588 | Apr 2017 → Feb 2020 | cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03008213 | Jan 2017 → Jan 2018 | chemotherapy-induced toxicity | Joseph Ma | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03040726 | May 2017 → Feb 2022 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01376297 | Jul 2011 → Sep 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01339260 | Apr 2011 → Nov 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06726291 | Feb 2024 → Dec 2025 overdue | endometrial cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 4 | NCT04817189 | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 4 | NCT03831633 | Sep 2018 → Jul 2019 | — | VIFORFRANCE | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT06331520 Background | May 2024 → Aug 2025 | chemotherapy-induced toxicity | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT03403712 Comparator | Mar → Sep 2018 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT02517021 Comparator | Nov 2015 → Aug 2016 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07254416 Background | Dec 2025 → Dec 2026 expected | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | netupitant | “Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron” NCT03386617 ↗15“containing 300 mg netupitant and 0.5 mg palonosetron).” NCT03831633 ↗ |
| Known as | NETU | “This post-hoc analysis evaluated the efficacy of NEPA, a fixed combination of netupitant (NETU [NK1RA]) and palonosetron (PALO [5-HT3RA]) in BC patients from two phase III studies.” PMID 28285236 ↗ Mar 2017 |
| Known as | Netupitant component of akynzeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL206253 ↗ |
| Known as | Netupitant component of akynzeo capsule | ChEMBL registry synonym — accepted as the source's own label CHEMBL206253 ↗ |
| Known as | RO 67-3189/000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206253 ↗ |
| Known as | RO-67-3189 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206253 ↗ |
| Action | Inhibit | “Netupitant and palonosetron are drugs that are thought to block the activation of certain types of chemicals in these areas (brain and gut)” NCT03386617 ↗1“Neurokinin 1 receptor antagonist” CHEMBL206253 ↗ |
| Modality | Small molecule | — CHEMBL206253 ↗ |
| Route | Oral | “Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle” NCT01339260 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL206253 ↗ |